BiotechTube

Brodalumab 210 mg + Placebo

Phase 2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

May 1, 2015 → May 1, 2015

NCT ID
NCT02429882

About Brodalumab 210 mg + Placebo

Brodalumab 210 mg + Placebo is a phase 2 stage product being developed by Amgen for Axial Spondyloarthritis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02429882. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (6) Terminated (1) Active (14)
✅AdalimumabAbbVieApproved
✅Secukinumab 150 milligram [Cosentyx]NovartisApproved
✅Secukinumab + Placebo + SecukinumabNovartisApproved
✅etanercept + etanercept + placeboPfizerApproved
✅Tofacitinib 5 MGPfizerApproved
✅Certolizumab PegolUCBApproved
🔄Brodalumab + PlaceboKyowa KirinPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02429882Phase 2Withdrawn

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
Brodalumab + PlaceboKyowa KirinPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
36
SHR-1314Jiangsu Hengrui MedicinePhase 1
29
UpadacitinibAbbViePre-clinical
33
AdalimumabAbbVieApproved
35
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
40
adalimumab + PlaceboAbbViePhase 3
40
TreatmentMerckPre-clinical
66
GolimumabMerckPhase 3
40
Tulisokibart + PlaceboMerckPhase 2
42
Secukinumab 150 milligram [Cosentyx]NovartisApproved
39
secukinumabNovartisPre-clinical
26
Secukinumab + PlaceboNovartisPhase 3
40
Secukinumab + Placebo + SecukinumabNovartisApproved
47
Secukinumab + Secukinumab and PlaceboNovartisPhase 3
40
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
40
Etanercept 25mg + SulfasalazinePfizerPhase 2
31